Oxytocin Acetate — Peptide Dosing Protocols reference
patient_educationexpert_opinion · status: needs_provider_reviewDetails
Summary (generated — provider review required)
Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) Protocol / Research Dosing Guide Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) An evidence-based oxytocin protocol guide covering intranasal, subcutaneous, and sublingual research routes, reconstitution math, supplies planning, side effects, and the boundary between FDA-approved obstetric use and investigational use. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Peptide Partners Shop View Peptide Partners Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Oxytocin Comparisons Related Protocols Blood Tests FAQ References Oxytocin Quick Start Oxytocin is a small peptide hormone made in the brain and released from the pituitary gland. In medicine, it is an FDA-approved drug given by IV or IM injection to start or strengthen labor, control bleeding after delivery, and support milk let-down.
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (10) · phenotypes (0)
evidence_reference, dosing_reference, monitoring_reference, mechanism, safety_reference
Findings (170) · awaiting review (132)
dosing · pending
This is not a dosing recommendation.
dosing · pending
Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) Protocol / Research Dosing Guide Oxytocin Peptide Dosing Guide: Routes, Reconstitution & Safety (2026) An evidence-based oxytocin protocol guide covering intranasal, subcutaneous, and sublingual research routes, reconstitution math, supplies planning, side effects, and the boundary between FDA-approved obstetric use and investigational use.
safety · pending
SOARS-B (24-week, N=290) reported no oxytocin-vs-placebo difference in serious adverse events.
dosing · pending
By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Peptide Partners Peptide Partners Shop View Peptide Partners Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Oxytocin Comparisons Related Protocols Blood Tests FAQ References Oxytocin Quick Start Oxytocin is a small peptide hormone made in the brain and released from the pituitary gland.
regulatory · pending
In medicine, it is an FDA-approved drug given by IV or IM injection to start or strengthen labor, control bleeding after delivery, and support milk let-down.
regulatory · pending
Those routes are not FDA-approved.
regulatory · pending
It separates what is approved from what is investigational, gives plain reconstitution math for common vial sizes, and is honest about where the evidence is strong versus weak.
regulatory · pending
Route Approved IV/IM in obstetrics.
dosing · pending
Intranasal (10-72 IU) and SubQ (100-500 mcg) are research-context only.
dosing · pending
Measure 1 IU of oxytocin is about 2 mcg of pure peptide.
dosing · pending
A 2 mg vial is about 1,000 IU; a 5 mg vial is about 2,500 IU.
dosing · pending
Reconstitute Common research lab practice: add 2-3 mL bacteriostatic water to a 2 mg or 5 mg lyophilized vial.
dosing · pending
Subcutaneous oxytocin does not cross the blood-brain barrier meaningfully.
outcome · pending
Mixed and largely negative for autism social outcomes after SOARS-B (NEJM 2021).
dosing · pending
Intranasal and subcutaneous oxytocin use outside of FDA-approved indications is investigational and should be discussed with a licensed clinician.
dosing · pending
Oxytocin Dosing Protocol & Schedule Oxytocin has very different dosing depending on route, because each route delivers a very different amount of the drug to the bloodstream and brain.
dosing · pending
The FDA-approved IV protocol for labor is dosed in milliunits per minute under continuous
monitoring · pending
monitoring.
dosing · pending
The intranasal and subcutaneous routes used in research are dosed in international units (IU) or micrograms (mcg) per session.
dosing · pending
Subcutaneous route (research context) Injection-site redness, bruising, or soreness.
mechanism · pending
If a research question depends on engaging brain oxytocin receptors, the intranasal route has stronger pharmacologic justification.
dosing · pending
Approved IV/IM obstetric label dosing The FDA-approved oxytocin injection label (Pitocin and synthetic oxytocin USP) describes induction or augmentation of labor by IV infusion only, started at a low rate and titrated to uterine response.
monitoring · pending
The usual starting infusion is around 0.5-1 milliunit per minute, raised gradually under continuous monitoring.
dosing · pending
This is not a dosing recommendation.
regulatory · pending
Obstetric oxytocin is hospital-only Per the FDA label, IV oxytocin can cause uterine hyperstimulation, water intoxication with seizures, and maternal or fetal complications.
monitoring · pending
It is only used under continuous clinical monitoring and is not part of any research-use protocol on this page.
dosing · pending
Intranasal Subcutaneous Sublingual / troche The most studied non-obstetric research route.
dosing · pending
Doses in published trials range from about 10 to 72 IU per session, though larger does not always mean stronger.
dosing · pending
A 2021 dose-response brain imaging study found that smaller doses (around 9-18 IU) sometimes produced larger amygd
dosing · pending
ala signals than 36 IU, consistent with the idea that oxytocin engages opposing intracellular pathways at higher concentrations.
dosing · pending
Intranasal oxytocin doses commonly reported in published research Trial context Single-dose social-cognition studies Per-session dose 24 IU Frequency in trial 1x Trial context Dose-response brain imaging Per-session dose 9, 18, or 36 IU Frequency in trial 1x Trial context SOARS-B autism RCT (Sikich 2021) Per-session dose Up to 48 IU/day total Frequency in trial Split twice daily Trial context Adult ASD trials (Anagnostou 2012, others) Per-session dose 24-48 IU/day total Frequency in trial Split twice daily Trial context Per-session dose Frequency in trial Single-dose social-cognition studies 24 IU 1x Dose-response brain imaging 9, 18, or 36 IU 1x SOARS-B autism RCT (Sikich 2021) Up to 48 IU/day total Split twice daily Adult ASD trials (Anagnostou 2012, others) 24-48 IU/day total Split twice daily These are study-arm doses pulled from published trials.
dosing · pending
They are not a dosing recommendation.
outcome · pending
Sprays should be aimed at the nasal mucosa, not the throat, and active nasal congestion likely reduces uptake.
dosing · pending
Subcutaneous oxytocin produces high plasma concentrations very quickly, but peripheral oxytocin does not cross the blood-brain barrier in meaningful amounts.
dosing · pending
That means subcutaneous dosing should not be expected to reproduce the behavioral effects seen with intranasal dosing.
dosing · pending
Subcutaneous oxytocin ranges seen in research-use protocols Range Low Per-dose amount 100 mcg Frequency seen in protocols Once daily Range Moderate Per-dose amount 200-300 mcg Frequency seen in protocols Once daily Range Upper Per-dose amount 400-500 mcg Frequency seen in protocols Once daily Range Per-dose amount Frequency seen in protocols Low 100 mcg Once daily Moderate 200-300 mcg Once daily Upper 400-500 mcg Once daily These ranges come from community and research-use protocols, not from human RCT efficacy data.
dosing · pending
ded sublingual troches usually carry per-dose amounts in the low-hundreds-of-IU range, but the human pharmacokinetic and efficacy data are limited compared with intranasal use.
dosing · pending
Cycle and review pattern seen in research-use protocols Approach Single dose Duration 1 session Review Point Same day Notes Used in many social-cognition studies; effects measured within 30-90 minutes.
outcome · pending
Approach Extended cycle Duration 24 weeks Review Point Week 12 Notes Mirrors the SOARS-B autism RCT length (which did not show benefit).
dosing · pending
Approach Duration Review Point Notes Single dose 1 session Same day Used in many social-cognition studies; effects measured within 30-90 minutes.
Processing
Processed into 30 searchable sections.